Drug Development Research Therapies White Paper 
Drug Discovery World
MARCH 27, 2023
Cell therapy research has never been more exciting with all of the research ongoing. Download this new white paper ‘Diving deep into cell therapy: An industry perspective’ to find out more.
Fierce BioTech
JULY 28, 2023
jsabatino Fri, 07/28/2023 - 11:29 In this white paper, we look at the past, present and future of antibodies as therapies, explaining how the modality became a key pillar of the biopharma industry—and looking forward to the methods and technologies that could unleash its full potential in the years to come. Download here!
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
FDA Law Blog: Drug Discovery
JANUARY 4, 2023
Brevig, Senior Regulatory Device and Biologics Expert — On December 7, 2022, FDA’s Center for Biologics Evaluation and Research (CBER) and the Office of Tissues and Advanced Therapies (OTAT) held a town hall to answer questions related to cell therapy and tissue-engineered products chemistry, manufacturing, and controls (CMC).
The Pharma Data
OCTOBER 16, 2020
This week’s round up features a digital solution for adapting clinical trials to ease the burden on the clinical research industry and an in vitro model that mimics the human airway epithelium using a newly developed technology platform. BetterLife conducts patient centric study via a fully remote clinical trial. Source link.
The Pharma Data
DECEMBER 28, 2020
Scopus is a biopharmaceutical company whose lead drug candidate is a novel, targeted immuno-oncology gene therapy for the treatment of multiple cancers. Dr. Hofstein completed his postdoctoral training and research in the Department of Neurobiology at Harvard Medical School. Hofstein received his B.Sc.
Conversations in Drug Development Trends
MARCH 12, 2024
For a more in-depth look at biomarkers, check out our white paper. Most IO Biomarkers Require Composite Use IO biomarkers can provide valuable data on a patient’s immune response to treatment and specification of which subpopulations would best benefit from immuno-oncology therapy.
Conversations in Drug Development Trends
APRIL 4, 2024
The ICH M10 guidelines aim to streamline this process, reducing redundancy in drug development and facilitating faster access to new therapies. Understanding and implementing the ICH M10 guidelines is not just a regulatory requirement; it’s a step towards more efficient and effective pharmaceutical research.
Expert insights. Personalized for you.
130 
Let's personalize your content